June 25, 2020 06:39 AM EDT
Financing
Startups

Yale spin­out re-en­gi­neers an im­munother­a­py GSK, oth­ers once aban­doned

Jason Mast

Editor

Be­gin­ning in 2004, Glax­o­SmithK­line ran 5 dif­fer­ent tri­als to see if giv­ing pa­tients a mol­e­cule called IL-18 could treat their can­cers. An ear­ly form of …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

No­vo Nordisk’s once-dai­ly he­mo­phil­ia drug Al­he­mo ap­proved in US

Bris­tol My­er­s' TYK2 in­hibitor suc­ceeds in pair of Phase 3 pso­ri­at­ic arthri­tis tri­als

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

A service from the Financial Times